VANCOUVER, British Columbia, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today announced that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming LEERINK Partners 7th Annual Global Healthcare Conference in New York, NY on Thursday, February 15th 2018 at 1:00 PM Eastern Time.
A live audio webcast and archive of the event will be available at: http://wsw.com/webcast/leerink30/aqxp/
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
The Trout Group
Source: Aquinox Pharmaceuticals, Inc.